Biotech Values

[RockRat]

RDHL -13% despite nominally positive phase-2 data in IBS-D

Towards the bottom of their PR:

>>RedHill is also analyzing drug allocation and pharmacokinetics in the study, including some aberrant findings which are not expected to have a material impact on the final results.<<

Given that they hit stat sig by a whisker - p=0.05 - an adverse change, even a small one, could torpedo the positive result. I follow RDHL loosely, because it's in my charity portfolio, but have never owned it. I haven't listened to the CC. It's been a while since I've looked at the competitive landscape in this indication; it could be that investors see the results as too meh to drive much sales.

Regards, RockRat